eXmoor Pharma and Signadori Bio have formed a partnership to develop gene-modified monocyte-derived macrophage cell therapies for the treatment of solid tumours. Signadori Bio is currently advancing its gene-modified monocyte therapy platform at the Gustave Roussy Institute, a recognised oncology centre.

Under the agreement, eXmoor Pharma will manage the technology translation and development process at its Cell & Gene Therapy Centre, supporting Signadori Bio’s progression from discovery to GMP-compliant manufacturing of its lead candidate. eXmoor will also provide an acting Head of CMC to join Signadori Bio’s management team. The collaboration aims to move the lead candidate toward GMP manufacturing and potential first-in-human clinical trials, with both companies working together on long-term process development.